Biogen

Hírek

Reuters - 16 órája

U.S. STOCKS Franchise Group, Connect Biopharma, OSI Systems

BUZZ-U.S. STOCKS ON THE MOVE-Franchise Group, Connect Biopharma, OSI Systems Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: https://refini.tv/3LI4BU7 The Morning News Call newsletter: https://refini.tv/3dKUyB8 The S&P 500 and the Dow Jones gained on Monday as a state-backed rescue of embattled lender Credit Suisse helped calm some jitters around a bigger banking crisis, while investors weighed odds of the Federal Reserve pausing its rate hikes this week.

Reuters - 18 órája

FDA staff says safety issues with Biogen's ALS drug to not prevent approval

UPDATE 2-FDA staff says safety issues with Biogen's ALS drug to not prevent approval Adds trial details By Bhanvi Satija March 20 (Reuters) - The U.S. health regulator's staff said on Monday safety issues with Biogen Inc's BIIB.O drug to treat an ultra-rare form of amyotrophic lateral sclerosis or ALS, also known as Lou Gehrig's disease, should not prevent its accelerated approval.

Reuters - 19 órája

US FDA staff flags no new safety concerns for Biogen's ALS drug

US FDA staff flags no new safety concerns for Biogen's ALS drug March 20 (Reuters) - The U.S. Food and Drug Administration's staff reviewers on Monday did not raise any new safety concerns about Biogen Inc's BIIB.O experimental drug for treating a rare type of amyotrophic lateral sclerosis, also known as Lou Gehrig's disease. Reporting by Raghav Ma

Reuters - 19 órája

U.S. STOCKS WestRock, PacWest, Foot Locker

BUZZ-U.S. STOCKS ON THE MOVE-WestRock, PacWest, Foot Locker Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: https://refini.tv/3LI4BU7 The Morning News Call newsletter: https://refini.tv/3dKUyB8 Wall Street's main indexes were set for a subdued open in volatile trading on Monday as investors weighed a state-backed takeover of Credit Suisse and the odds of the Federal Reserve keeping interest rates unchanged this week.

Reuters - 5 napja

Biogen Receives Favorable Decision From European Union's Court Of Justice On TECFIDERA Regulatory Data

BRIEF-Biogen Receives Favorable Decision From European Union's Court Of Justice On TECFIDERA Regulatory Data March 16 (Reuters) - Biogen Inc BIIB.O : BIOGEN RECEIVES FAVORABLE DECISION FROM COURT OF JUSTICE OF THE EUROPEAN UNION RELATING TO TECFIDERA® (DIMETHYL FUMARATE) REGULATORY DATA AND MARKETING PROTECTION BIOGEN - BELIEVES TECFIDERA IS ENTIT

Reuters - 5 napja

Alzheimer's Association lobbies for Medicare coverage of Leqembi and other drugs

FOCUS-Alzheimer's Association lobbies for Medicare coverage of Leqembi and other drugs By Ahmed Aboulenein WASHINGTON, March 16(Reuters) - The Alzheimer's Association has deployed 1,000 people diagnosed with, or caring for someone with the disease, to meet with all 535 members of Congress across the United States and urge them to press Medicare for early access to a new class of drugs, beginning with lecanemab, that promise to slow the disease.

Reuters - 6 napja

Biogen Says Exposure To Credit Suisse Is Immaterial

BRIEF-Biogen Says Exposure To Credit Suisse Is Immaterial March 15 (Reuters) - Biogen Inc BIIB.O : BIOGEN SAYS EXPOSURE TO CREDIT SUISSE IS IMMATERIAL Further company coverage: BIIB.O

Reuters - 1 hete

Biogen Appoints Chuck Triano As Head Of Investor Relations

BRIEF-Biogen Appoints Chuck Triano As Head Of Investor Relations March 14 (Reuters) - Biogen Inc BIIB.O : BIOGEN APPOINTS CHUCK TRIANO AS HEAD OF INVESTOR RELATIONS Source text for Eikon: ID:nGNXZBrqS Further company coverage: BIIB.O

Reuters - 1 hete

US VA to cover Eisai, Biogen Alzheimer's treatment Leqembi

UPDATE 1-US VA to cover Eisai, Biogen Alzheimer's treatment Leqembi Adds background, link to VA document March 13 (Reuters) - Eisai Co Ltd 4523.T and Biogen Inc BIIB.O said on Monday that the U.S. Department of Veteran Affairs (VA) will provide coverage of their Alzheimer's treatment Leqembi to veterans at an early stage of the memory-robbing disease.

Reuters - 1 hete

U.S. Veterans' Health Administration providing coverage of Eisai's Alzheimer's treatment Leqembi

U.S. Veterans' Health Administration providing coverage of Eisai's Alzheimer's treatment Leqembi March 13 (Reuters) - Eisai Co Ltd 4523.T said on Monday, that the U.S. Veterans' Health Administration (VHA) is providing coverage of its treatment Leqembi to veterans living with early stages of Alzheimer's disease. Reporting by Pratik Jain

Reuters - 2 hete

Caroline Dorsa To Succeed Stelios Papadopoulos As Chair Of Biogen Board Of Directors

BRIEF-Caroline Dorsa To Succeed Stelios Papadopoulos As Chair Of Biogen Board Of Directors March 8 (Reuters) - Biogen Inc BIIB.O : CAROLINE DORSA TO SUCCEED STELIOS PAPADOPOULOS AS CHAIR OF BIOGEN BOARD OF DIRECTORS BIOGEN INC - BOARD HAS ELECTED CAROLINE DORSA AS CHAIR OF BOARD, EFFECTIVE IMMEDIATELY BIOGEN INC - DORSA WILL SUCCEED STELIOS PAPADOP

Reuters - 2 hete

Sage Therapeutics & Biogen Share Update On FDA Advisory Committee For Zuranolone

BRIEF-Sage Therapeutics & Biogen Share Update On FDA Advisory Committee For Zuranolone March 8 (Reuters) - SAGE Therapeutics Inc SAGE.O : SAGE THERAPEUTICS AND BIOGEN SHARE UPDATE ON FDA ADVISORY COMMITTEE FOR ZURANOLONE SAGE THERAPEUTICS INC - FDA HAS ASSIGNED A PRESCRIPTION DRUG USER FEE ACT (PDUFA) ACTION DATE OF AUGUST 5, 2023 SAGE THERAPEUTICS

Reuters - 2 hete

Caroline Dorsa To Succeed Stelios Papadopoulos As Chair Of Biogen Board Of Directors

BRIEF-Caroline Dorsa To Succeed Stelios Papadopoulos As Chair Of Biogen Board Of Directors March 8 (Reuters) - Biogen Inc BIIB.O : CAROLINE DORSA TO SUCCEED STELIOS PAPADOPOULOS AS CHAIR OF BIOGEN BOARD OF DIRECTORS BIOGEN INC - BOARD OF DIRECTORS HAS ELECTED CAROLINE DORSA AS CHAIR OF BOARD OF DIRECTORS, EFFECTIVE IMMEDIATELY Source text for Eikon

Reuters - 2 hete

Eisai, Biogen say FDA grants priority review for Alzheimer's drug Lecanemab

Eisai, Biogen say FDA grants priority review for Alzheimer's drug Lecanemab TOKYO, March 6 (Reuters) - Japanese drugmaker Eisai Co Ltd 4523.T and its U.S. partner Biogen Inc BIIB.O said on Monday that the U.S. Food and Drug Administration granted priority review for traditional approval of their Alzheimer's treatment Lecanemab. The FDA accepted Eisai's supplemental Biologics License Application for the drug, supporting transition from the accelerated approval granted in January, the drugmaker sa

Reuters - 2 hete

Eisai Co Ltd FDA Accepts Eisai's Filing Of A Sbla Of Leqembi (Lecanemab) For Treatment Of Alzheimer's Disease And Grants Priority Review

BRIEF-Eisai Co Ltd FDA Accepts Eisai's Filing Of A Sbla Of Leqembi (Lecanemab) For Treatment Of Alzheimer's Disease And Grants Priority Review March 6 (Reuters) - Eisai Co Ltd 4523.T : EISAI CO LTD: FDA ACCEPTS EISAI'S FILING OF A SBLA OF LEQEMBI (LECANEMAB) FOR TREATMENT OF ALZHEIMER'S DISEASE AND GRANTS PRIORITY REVIEW Source text for Eikon: ID:n

Reuters - 2 hete

FDA Accepts Eisai’s Filing Of Grants Priority Review For Traditional Approval Of Leqembi For Treatment Of Alzheimer’s Disease

BRIEF-FDA Accepts Eisai’s Filing Of Grants Priority Review For Traditional Approval Of Leqembi For Treatment Of Alzheimer’s Disease March 5 (Reuters) - Biogen Inc BIIB.O : FDA ACCEPTS EISAI’S FILING OF A SUPPLEMENTAL BIOLOGICS LICENSE APPLICATION AND GRANTS PRIORITY REVIEW FOR TRADITIONAL APPROVAL OF LEQEMBI™ (LECANEMAB-IRMB) FOR THE TREATM

Reuters - 3 hete

Biogen Japan, Eisai terminate co-promotion agreement for multiple sclerosis drugs in Japan

BRIEF-Biogen Japan, Eisai terminate co-promotion agreement for multiple sclerosis drugs in Japan March 2 (Reuters) - Eisai Co Ltd 4523.T : BIOGEN JAPAN, EISAI TERMINATE CO-PROMOTION AGREEMENT FOR MULTIPLE SCLEROSIS DRUGS IN JAPAN Source text for Eikon: [ID:] Further company coverage: 4523.T Reporting by Elaine Lies

Reuters - 3 hete

Genentech sues Biogen for royalties on blockbuster MS drug

UPDATE 1-Genentech sues Biogen for royalties on blockbuster MS drug Adds comment from Genentech By Blake Brittain March 1 (Reuters) - Roche's Genentech Inc ROGING.UL sued Biogen MA Inc BIIB.O on Tuesday in San Francisco federal court, claiming Biogen owes additional patent royalties from worldwide sales of its blockbuster multiple-sclerosis and Crohn's disease drug Tysabri.

Reuters - 3 hete

Genentech sues Biogen for royalties on blockbuster MS drug

Genentech sues Biogen for royalties on blockbuster MS drug By Blake Brittain March 1 (Reuters) - Roche's Genentech Inc ROGING.UL sued Biogen MA Inc BIIB.O on Tuesday in San Francisco federal court, claiming Biogen owes additional patent royalties from worldwide sales of its blockbuster multiple-sclerosis and Crohn's disease drug Tysabri. Genentech's lawsuit said Biogen owes royalties for all the Tysabri that was produced using Genentech's patents before the patents expired, even if it was sold l

Reuters - 3 hete

Reata shares triple after surprise FDA nod for rare disease drug

UPDATE 2-Reata shares triple after surprise FDA nod for rare disease drug Updates share price activity March 1 (Reuters) - Shares of Reata Pharmaceuticals Inc RETA.O tripled in value on Wednesday after the U.S. Food and Drug Administration (FDA) approved its rare disease drug , ending years of uncertainty over its future. The U.S. biotech firm's shares jumped to $ 93, the highest since late 2021, on more than 16 million shares traded, a record one-day volume for the stock.

Feltételek

Népszerű eszközök

Felelősségkizáró nyilatkozat: Az XM Group entitásai csak végrehajtási szolgáltatást és online kereskedési platformunkhoz való hozzáférést biztosítanak, ami lehetővé teszi, hogy a felhasználók megtekinthessék és/vagy felhasználhassák a honlapon vagy azon keresztül elérhető tartalmakat, amelyek nem módosíthatók és nem egészíthetők ki. A hozzáférés és felhasználás mindig a következők függvénye: (i) Felhasználási feltételek; (ii) Kockázati figyelmeztetés; valamint (iii) Teljes felelősségkizáró nyilatkozat. Az ilyen tartalmakat ezért csupán általános információként biztosítjuk. Külön felhívjuk figyelmét arra, hogy az online kereskedési platformunkon található tartalmak nem felhívások vagy ajánlatok tranzakciókba történő belépésre a pénzügyi piacokon. A pénzügyi piacokon folytatott kereskedés jelentős kockázattal jár a tőkéjére nézve.

Az online kereskedési platformunkon közzétett anyagok kizárólag oktatási / tájékoztatási célt szolgálnak, és nem tartalmaznak (nem tekinthető úgy, hogy tartalmaznak) pénzügyi, befektetési adóügyi vagy kereskedési tanácsokat vagy ajánlásokat, illetve kereskedési áraink jegyzékét, vagy bármilyen pénzügyi instrumentummal végrehajtott tranzakcióra vonatkozó ajánlatot vagy felhívást, vagy Önnek szóló kéretlen pénzügyi promóciókat.

Az ezen a honlapon szereplő, külső felektől származó, valamint az XM által készített tartalmak, például vélemények, hírek, kutatások, elemzések, árak és egyéb információk vagy külső felek oldalaira utaló hivatkozások „jelenlegi állapotukban”, általános piaci magyarázatként jelennek meg, és nem minősülnek befektetési tanácsnak. Amennyiben bármely tartalom befektetéssel kapcsolatos kutatásként értelmezhető, meg kell értenie és el kell fogadnia, hogy a tartalom nem a befektetéssel kapcsolatos kutatás függetlenségének előmozdítására szolgáló jogi követelmények szerint készült, következésképpen a vonatkozó törvények és jogszabályok szerint marketingkommunikációnak minősül. Kérjük, feltétlenül olvassa el és értse meg a fenti információkkal kapcsolatos „nem független befektetéskutatással kalcsolatos tájékoztatónkat” és a kockázati figyelmeztetésünket, amelyek itt érhetők el.

Biogen

Hírek

Feltételek

Népszerű eszközök

XM élő chat